Cargando…
Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation
Stroke is a leading cause of morbidity and mortality worldwide. Atrial fibrillation (AF) is an independent risk factor for stroke, increasing the risk five-fold. Strokes in patients with AF are more likely than other embolic strokes to be fatal or cause severe disability and are associated with high...
Autores principales: | Camm, A. John, Pinto, Fausto J., Hankey, Graeme J., Andreotti, Felicita, Hobbs, F.D. Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482288/ https://www.ncbi.nlm.nih.gov/pubmed/26116685 http://dx.doi.org/10.1093/europace/euv068 |
Ejemplares similares
-
Special considerations for therapeutic choice of non–vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillation
por: Okumura, Ken, et al.
Publicado: (2016) -
Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation
por: Diener, Hans-Christoph, et al.
Publicado: (2020) -
Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial
por: Hohnloser, Stefan H, et al.
Publicado: (2020) -
Data from a multidisciplinary poll of 178 expert physicians on the usage of non-vitamin K Oral Anticoagulants in patients with atrial fibrillation and venous thromboembolism
por: Colonna, Paolo, et al.
Publicado: (2017) -
Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
por: Peeters, Frederique E. C. M., et al.
Publicado: (2018)